Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.

NCT03843905 · clinicaltrials.gov ↗

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms
Microbiota
Prognosis
Metabolic Syndrome
Sarcopenia

Interventions

OTHER: no intervention

Sponsor

University Hospital, Clermont-Ferrand

Collaborators

[object Object]
[object Object]